NCT01388790已完成2 期
Open-label, Single-arm, Multicenter Phase II Trial Investigating Cetuximab in Combination With S-1 and Cisplatin as First-line Treatment for Patients With Advanced Gastric Adenocarcinoma Including Adenocarcinoma of the Gastroesophageal Junction
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Best Overall Response (BOR) Rate - Independent Review Committee (IRC) Assessments
研究概览
简要总结
This open-label, single-arm, multicenter, Phase 2 trial will treat at least 40 participants with advanced gastric adenocarcinoma including adenocarcinoma of the gastroesophageal junction (GEJ) who have not previously received systemic chemotherapy for this setting.
All eligible participants will receive the combination of cetuximab plus S-1 (a combination of tegafur, gimeracil, and oteracil) and cisplatin.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent and agreement with medically accepted contraception (in participants with conception potential) are obtained
- •Japanese participants aged greater than or equal to 20 years
- •Histologically confirmed adenocarcinoma of the stomach or GEJ (adenocarcinomas of the esophagogastric junction types I to III according to Siewert's classification) in Stage M0 (unresectable advanced) or Stage M1 (unresectable metastatic) of the disease
- •Archived tumor material sample for at least subsequent standardized epidermal growth factor receptor (EGFR) expression and Kirsten-rat sarcoma (KRAS) mutation assessments
- •At least one radiographically documented measurable lesion in a previously non-irradiated area according to the RECIST v 1.0
- •Eastern Cooperative Oncology Group - performance status (ECOG-PS) 0 to 1
- •Estimated life expectancy greater than 12 weeks
- •Renal, liver and hematopoietic function as defined in the protocol.
- •Sodium and potassium within normal limits or as defined in the protocol
- •Other protocol defined inclusion criteria could apply
排除标准
- •Prior therapies: prior treatment with an antibody or molecule targeting EGFR- and/or vascular endothelial growth factor (VEGF) receptor-related signaling pathways; chemotherapies; or radiotherapies, major surgeries, and any investigational drugs in the 30 days before the start of trial treatment
- •Concurrent chronic systemic immune or hormone therapy not indicated in this trial protocol any contraindication to treatment with cetuximab and cisplatin, or any treatments with prohibited concomitant drugs
- •Brain metastasis and/or leptomeningeal disease
- •Clinically relevant coronary artery disease (New York Heart Association [NYHA] functional angina classification III/IV), congestive heart failure (NYHA III/IV), clinically relevant cardiomyopathy, history of myocardial infarction in the last 12 months, or high risk of uncontrolled arrhythmia
- •Chronic diarrhea or short bowel syndrome
- •Known Human Immunodeficiency Virus (HIV) infection, active or chronic carrier of hepatitis B virus (HBV) (HBV antigen positive or HBV deoxyribonucleic acid (DNA) positive) or hepatitis C virus (HCV) (HCV antibody positive)
- •Pregnancy or lactation period
- •Concurrent treatment with a non-permitted drug (any other chemotherapy, systemic anticancer therapy or immunotherapy)
- •Previous malignancy other than gastric cancer in the last 5 years Medical or psychological conditions that would not permit the participant to complete the trial or sign the Informed Consent Form (ICF)
- •Legal incapacity or limited legal capacity
- •Other protocol defined exclusion criteria could apply
研究组 & 干预措施
Cetuximab plus cisplatin plus S-1
Experimental
干预措施: Cetuximab (Drug)
Cetuximab plus cisplatin plus S-1
Experimental
干预措施: Cisplatin (Drug)
Cetuximab plus cisplatin plus S-1
Experimental
干预措施: S-1 (Drug)
结局指标
主要结局
Best Overall Response (BOR) Rate - Independent Review Committee (IRC) Assessments
时间窗: Evaluations were performed every 6 weeks until disease progression, reported between day of first participant treated, that is July 2011, until cut-off date, (14 August 2012)
The best overall response rate is defined as the percentage of participants having achieved confirmed complete response plus partial response as the best overall response according to radiological assessments (based on Response Evaluation Criteria in Solid Tumors version 1.0 \[RECIST v 1.0\] criteria).
次要结局
- Median Progression-free Survival (PFS) Time - Independent Review Committee (IRC) Assessments(Time from start of treatment to disease progression, death or last tumor assessment, reported between day of first participant treated, that is July 2011, until cut-off date, (14 August 2012))
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
2 期
TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC)Non-small Cell Lung CancerNCT05955391Shenzhen TargetRx, Inc.164
招募中
2 期
A Phase II Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Cervical CancerCervical CancerNCT05557565Qilu Pharmaceutical Co., Ltd.150
终止
1 期
A Clinical Trial to Asses Efficacy and Safety of Cord Blood Eye Drops in Neurotrophic KeratopathyNeurotrophic KeratopathyNCT03084861Banc de Sang i Teixits9
招募中
2 期
NCCH2006/MK010 Trial (FORTUNE Trial)Advanced or Recurrent Solid TumorsFGFR Gene AlterationsNCT04962867National Cancer Center, Japan75
终止
2 期
BIBW 2992 (Afatinib) and VinorelbineCarcinoma Breast Stage IVNCT01531764University of Magdeburg2